Monitor upcoming clinical updates for SENTI-202 and watch for potential financing activity given reduced cash levels. The RMAT designation may accelerate development but does not guarantee approval.
Price Chart
Executive Summary
Senti Biosciences reported Q4 and full-year 2025 financial results, showing a narrowed net loss compared to the prior year despite minimal revenue. The company highlighted positive clinical data for its lead candidate SENTI-202 in AML and received RMAT designation from the FDA. Cash balance declined to $16.4 million, raising near-term liquidity concerns.
Key Financial Metrics
Key Facts
- Cash and cash equivalents dropped to $16.4 million as of December 31, 2025, from $48.3 million a year earlier
- Net loss for full-year 2025 was $61.4 million, improved from $52.8 million in 2024 despite non-recurring $5.1 million impairment
- Revenue was $22,000 for the year, up from $0 in 2024
- Received RMAT designation from FDA for SENTI-202 in relapsed/refractory AML
- R&D expenses increased to $37.6 million in 2025 from $34.4 million in 2024
- G&A expenses decreased to $26.2 million in 2025 from $26.4 million in 2024
Financial Impact
Cash burn of $31.9 million in 2025 ($61.4M net loss offset by non-cash items and income from related-party arrangements); revenue remains negligible at $22K
Risk Factors
- Low cash balance of $16.4M may necessitate near-term dilutive financing
- Minimal revenue and continued losses raise sustainability concerns
- Heavy reliance on a single clinical candidate (SENTI-202) with unproven commercial potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263731 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | DEFA14A | $0.2408 $0.2175 | ▼ −9.68% | ▼ −10.13% | $0.1725 (−28.36%) |
Oct 13, 2026 12d ago | 8-K | $0.2408 $0.2175 | ▲ +9.68% | ▲ +10.13% | $0.1725 (+28.36%) |
Sep 25, 2026 4w ago | EFFECT | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1725 (+47.62%) |
Sep 24, 2026 4w ago | DEFM14A | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1725 (+47.62%) |
Sep 22, 2026 4w ago | S-3/A | $0.3156 $0.3075 | ▲ +2.57% | ▲ +1.38% | $0.1725 (+45.34%) |
Sep 10, 2026 6w ago | S-3/A | $0.3060 $0.3200 | ▼ −4.58% | ▼ −4.80% | $0.1725 (+43.63%) |
Sep 4, 2026 7w ago | DEFA14A | $0.3326 $0.3021 | ▼ −9.17% | ▼ −7.96% | $0.1725 (−48.14%) |
Sep 4, 2026 7w ago | 8-K | $0.3326 $0.3021 | ▲ +9.17% | ▲ +7.96% | $0.1725 (+48.14%) |
Aug 20, 2026 9w ago | 8-K | $0.3886 $0.3770 | ▲ +2.99% | ▲ +3.46% | $0.1725 (+55.61%) |
Jul 16, 2026 14w ago | S-3/A | $0.4597 $0.4266 | ▲ +7.20% | ▲ +5.53% | $0.1725 (+62.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers